Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 25% Improvement Relative Risk c19hcq.org Taccone et al. HCQ for COVID-19 ICU PATIENTS Favors HCQ Favors control
The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium
Taccone et al., The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019
Taccone et al., The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium, The Lancet Regional Health - Europe, doi:10.1016/j.lanepe.2020.100019
Dec 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,747 ICU patients in Belgium showing lower mortality with HCQ, multivariate mixed effects analysis HCQ aOR 0.64 [0.45-0.92].
risk of death, 24.7% lower, RR 0.75, p = 0.02, treatment 449 of 1,308 (34.3%), control 183 of 439 (41.7%), NNT 14, odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Taccone et al., 23 Dec 2020, retrospective, Belgium, peer-reviewed, 10 authors, average treatment delay 5.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: The Lancet Regional Health - Europe 2 (2021) 100019 Contents lists available at ScienceDirect The Lancet Regional Health - Europe journal homepage: www.elsevier.com/lanepe Research paper The role of organizational characteristics on the outcome of COVID-19 patients admitted to the ICU in Belgium Fabio Silvio Tacconea,1,*, Nina Van Goethemb,1,*, Robby De Pauwb, Xavier Wittebolec, Koen Blotb, Herman Van Oyenb,d, Tinne Lernoutb, Marion Montourcyb, Geert Meyfroidte,#, Dominique Van Beckhovenb,#, on behalf of the Belgian Society of Intensive Care Medicine and the Belgian Collaborative Group on COVID-19 Hospital Surveillance Department of Intensive Care, Erasme Hospital, Universite Libre de Bruxelles (ULB), Brussels, Belgium Department of Epidemiology and Public Health, Sciensano, Brussels, Belgium Department of Intensive Care, Cliniques Universitaires Saint-Luc, UCLouvain, Brussels, Belgium d Department of Public Health and Primary Care, University of Gent, Gent, Belgium e Department of Intensive Care Medicine, University of Leuven, Leuven, Belgium a b c A R T I C L E I N F O Article History: Received 28 October 2020 Revised 6 December 2020 Accepted 18 December 2020 Available online 23 December 2020 Keywords: COVID-19 Mortality Intensive care unit Organisation Surge A B S T R A C T Background: Several studies have investigated the predictors of in-hospital mortality for COVID-19 patients who need to be admitted to the Intensive Care Unit (ICU). However, no data on the role of organizational issues on patients’ outcome are available in this setting. The aim of this study was therefore to assess the role of surge capacity organisation on the outcome of critically ill COVID-19 patients admitted to ICUs in Belgium. Methods: We conducted a retrospective analysis of in-hospital mortality in Belgian ICU COVID-19 patients via the national surveillance database. Non-survivors at hospital discharge were compared to survivors using multivariable mixed effects logistic regression analysis. Specific analyses including only patients with invasive ventilation were performed. To assess surge capacity, data were merged with administrative information on the type of hospital, the baseline number of recognized ICU beds, the number of supplementary beds specifically created for COVID-19 ICU care and the “ICU overflow” (i.e. a time-varying ratio between the number of occupied ICU beds by confirmed and suspected COVID-19 patients divided by the number of recognized ICU beds reserved for COVID-19 patients; ICU overflow was present when this ratio is  1.0). Findings: Over a total of 13,612 hospitalised COVID-19 patients with admission and discharge forms registered in the surveillance period (March, 1 to August, 9 2020), 1903 (14.0%) required ICU admission, of whom 1747 had available outcome data. Non-survivors (n = 632, 36.1%) were older and had more frequently various comorbid diseases than survivors. In the multivariable analysis, ICU overflow, together with older age, presence of comorbidities, shorter delay between symptom onset and hospital admission, absence of hydroxychloroquine therapy and use of invasive mechanical ventilation and of ECMO, was independently associated with an increased in-hospital mortality. Similar results were found in in in the subgroup of invasively ventilated patients. In addition, the proportion of supplementary beds specifically created for COVID-19 ICU care to the previously existing total number of ICU beds was associated..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit